Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.

Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.

the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

Inclusion Criteria:

• high risk t (8; 21) AML
• molecular relapse after allo-SCT

Exclusion Criteria:

• active graft-versus-host disease
• uncontrolled severe infection
• organ function failure